CO6351736A2 - Polimorfo b de la n-(2-aminofelil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil] benzamida (ms-275) - Google Patents

Polimorfo b de la n-(2-aminofelil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil] benzamida (ms-275)

Info

Publication number
CO6351736A2
CO6351736A2 CO11024240A CO11024240A CO6351736A2 CO 6351736 A2 CO6351736 A2 CO 6351736A2 CO 11024240 A CO11024240 A CO 11024240A CO 11024240 A CO11024240 A CO 11024240A CO 6351736 A2 CO6351736 A2 CO 6351736A2
Authority
CO
Colombia
Prior art keywords
benzamide
methyl
polymorph
methoxycarbonylamino
aminophenyl
Prior art date
Application number
CO11024240A
Other languages
English (en)
Inventor
Mathhias Schneider
Michael Gottfried
Gabriele Winter
Jens Geisler
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41133825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6351736(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CO6351736A2 publication Critical patent/CO6351736A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

El polimorfo B cristalino de N-(2-aminofenil)-4-[N-(piridin-3-il) metoxicarbonilamino-metil] benzamida (MS-275) de fórmula I:que está sustancialmente libre de polimorfo A de N-(2- aminofenil)-4-[N-(piridin-3-il)metoxi carbonilamino-metil] benzamida, y donde su difractograma de rayos X tiene una reflexión a 2-theta = 21,1°, 20,4° y 27,4° y el espectro Raman tiene bandas en 902 cm-1, 3036 cm-1, 1639 cm-1 y 916 cm-1, y el espectro IR (ATR) tiene bandas en 1702 cm-1, 3311 cm-1, 1641 cm-1, 1262 cm-1 y 751 cm-1.También se describe un proceso para producir el compuesto polimorfo B cristalino de N-(2-aminofenil)-4-[N- (piridin-3-il)metoxi carbonilamino-metil] benzamida, su uso para la producción de un medicamento para tratar tumores malignos, enfermedades autoinmunes, enfermedades dermatológicas y parasitismo, así como composiciones que lo comprenden solo o en combinación con un diluyente y/o un vehículo farmacéuticamente aceptable, y combinaciones para la administración simultánea, por separado o en secuencia que lo comprenden junto con uno o más agentes citotóxicos o citolíticos.
CO11024240A 2008-08-29 2011-02-28 Polimorfo b de la n-(2-aminofelil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil] benzamida (ms-275) CO6351736A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9304608P 2008-08-29 2008-08-29
EP08163274 2008-08-29

Publications (1)

Publication Number Publication Date
CO6351736A2 true CO6351736A2 (es) 2011-12-20

Family

ID=41133825

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11024240A CO6351736A2 (es) 2008-08-29 2011-02-28 Polimorfo b de la n-(2-aminofelil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil] benzamida (ms-275)

Country Status (36)

Country Link
US (2) US7973166B2 (es)
EP (1) EP2350005B1 (es)
JP (1) JP4921616B2 (es)
KR (1) KR101073760B1 (es)
CN (1) CN102137846B (es)
AR (1) AR073226A1 (es)
AT (1) ATE538094T1 (es)
AU (1) AU2009286982C1 (es)
BR (1) BRPI0918580B8 (es)
CA (1) CA2735294C (es)
CO (1) CO6351736A2 (es)
CR (2) CR20110107A (es)
CY (1) CY1112645T1 (es)
DK (1) DK2350005T3 (es)
DO (1) DOP2011000064A (es)
EA (1) EA016811B1 (es)
EC (1) ECSP11010849A (es)
ES (1) ES2378640T3 (es)
HK (1) HK1160107A1 (es)
HN (1) HN2011000609A (es)
HR (1) HRP20120183T8 (es)
IL (1) IL211276A (es)
MA (1) MA32610B1 (es)
MX (1) MX2011002248A (es)
MY (1) MY149058A (es)
NZ (1) NZ591387A (es)
PE (2) PE20141062A1 (es)
PL (1) PL2350005T3 (es)
PT (1) PT2350005E (es)
RS (1) RS52164B (es)
SI (1) SI2350005T1 (es)
SM (1) SMT201200026B (es)
SV (1) SV2011003846A (es)
TW (1) TWI427062B (es)
WO (1) WO2010022988A1 (es)
ZA (1) ZA201102285B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2350005T3 (da) 2008-08-29 2012-03-19 Bayer Pharma AG N-(2-aminophenyl)-4-[N-(pyridin-3-yl)-methoxy-carbonyl-aminomehtyl]benzamid(MS-275)-polymorf B
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
FR2977492B1 (fr) * 2011-07-04 2013-07-05 Servier Lab Nouvelle association entre le n-hydroxy-4-{2-[3-(n,n-dimethylaminomethyl) benzofuran-2-ylcarbonylamino]ethoxy}benzamide et le folfox
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
JP2017537084A (ja) 2014-11-12 2017-12-14 トラコン ファーマシューティカルズ、インコーポレイテッド 抗エンドグリン抗体及びその用途
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
EP3168210A1 (en) 2015-11-13 2017-05-17 Sandoz Ag Crystalline forms of entinostat
WO2017216761A1 (en) * 2016-06-17 2017-12-21 Dr. Reddy's Laboratories Limited Solid forms of entinostat
WO2019019130A1 (zh) * 2017-07-28 2019-01-31 杭州领业医药科技有限公司 含恩替诺特的化合物，其化合物晶型及其制备方法和药物组合物
KR20240019100A (ko) 2021-05-10 2024-02-14 맥파란 스미스 리미티드 엔티노스타트의 신규 형태

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
JP3354090B2 (ja) * 1996-09-30 2002-12-09 シエーリング アクチエンゲゼルシャフト 分化誘導剤
JP4030683B2 (ja) * 1998-07-24 2008-01-09 三井化学株式会社 ベンズアミド誘導体の合成法
US6320078B1 (en) * 1998-07-24 2001-11-20 Mitsui Chemicals, Inc. Method of producing benzamide derivatives
JP2001064177A (ja) * 1999-08-16 2001-03-13 Schering Ag ベンズアミド誘導体を有効成分とする製剤
JP4360660B2 (ja) * 1999-11-09 2009-11-11 三井化学株式会社 モノアシルフェニレンジアミン誘導体の精製法
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
DK2350005T3 (da) 2008-08-29 2012-03-19 Bayer Pharma AG N-(2-aminophenyl)-4-[N-(pyridin-3-yl)-methoxy-carbonyl-aminomehtyl]benzamid(MS-275)-polymorf B

Also Published As

Publication number Publication date
PE20141062A1 (es) 2014-09-19
WO2010022988A1 (en) 2010-03-04
JP2012500819A (ja) 2012-01-12
PT2350005E (pt) 2012-03-12
KR20110038187A (ko) 2011-04-13
US20100056585A1 (en) 2010-03-04
CN102137846A (zh) 2011-07-27
ZA201102285B (en) 2011-12-28
HRP20120183T8 (en) 2012-11-30
AU2009286982C1 (en) 2012-04-26
CN102137846B (zh) 2014-04-23
NZ591387A (en) 2012-03-30
MY149058A (en) 2013-07-15
PE20110677A1 (es) 2011-09-16
JP4921616B2 (ja) 2012-04-25
KR101073760B1 (ko) 2011-10-13
EA016811B1 (ru) 2012-07-30
CY1112645T1 (el) 2016-02-10
SI2350005T1 (sl) 2012-03-30
DK2350005T3 (da) 2012-03-19
AU2009286982A1 (en) 2010-03-04
CA2735294C (en) 2013-10-15
SV2011003846A (es) 2011-07-27
BRPI0918580A8 (pt) 2017-07-11
BRPI0918580A2 (pt) 2015-12-01
AR073226A1 (es) 2010-10-20
EP2350005B1 (en) 2011-12-21
PL2350005T3 (pl) 2012-05-31
IL211276A0 (en) 2011-04-28
HRP20120183T1 (hr) 2012-03-31
AU2009286982B2 (en) 2011-06-23
USRE45499E1 (en) 2015-04-28
US7973166B2 (en) 2011-07-05
DOP2011000064A (es) 2011-03-31
EP2350005A1 (en) 2011-08-03
CR20160465A (es) 2016-12-06
CA2735294A1 (en) 2010-03-04
HN2011000609A (es) 2014-09-29
EA201100354A1 (ru) 2011-10-31
ECSP11010849A (es) 2011-03-31
SMT201200026B (it) 2012-07-10
BRPI0918580B1 (pt) 2020-11-24
RS52164B (en) 2012-08-31
TWI427062B (zh) 2014-02-21
ES2378640T3 (es) 2012-04-16
MX2011002248A (es) 2011-03-29
MA32610B1 (fr) 2011-09-01
TW201014820A (en) 2010-04-16
IL211276A (en) 2014-07-31
CR20110107A (es) 2011-04-28
HK1160107A1 (en) 2012-08-10
BRPI0918580B8 (pt) 2021-05-25
ATE538094T1 (de) 2012-01-15

Similar Documents

Publication Publication Date Title
CO6351736A2 (es) Polimorfo b de la n-(2-aminofelil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil] benzamida (ms-275)
PH12015502323A1 (en) Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
HK1113352A1 (en) Chemical compounds
HK1114375A1 (en) Chemical compounds
MY156814A (en) Organic compounds and their uses
MX340573B (es) Proceso para la fabricacion de compuestos farmaceuticamente activos.
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
NZ603155A (en) Phospholipid drug analogs
PA8785401A1 (es) Derivados de bencimidazol
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
BR112012016797A2 (pt) intensificador dinâmico de baixo utilizando compressor com equalizador incorporado
IN2012DN03182A (es)
SI2150530T1 (sl) Substituirani sulfonamidni derivati
MY186456A (en) Quinazoline carboxamide azetidines
TW200633977A (en) Novel process for the manufacture of 3-pyrrolidin-2-yl-propionic acid derivatives
TW200716564A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
UA97806C2 (ru) Бензиламины, способ их получения и их применения в качестве противовоспалительных средств
TW200621703A (en) Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
TW200726752A (en) Process for the production of intermediates for the preparation of tricyclic benzimidazoles
TW200613317A (en) Steroid prodrugs with androgenic action
UA106967C2 (uk) Протипухлинні аналоги пептидів, фармацевтична композиція, спосіб одержання сполук та проміжні сполуки
MX2007008349A (es) Nueva sintesis de una etapa de aminas disustituidas utiles.
CU24049B1 (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil] benzamida (ms-275)